Nventa Biopharmaceuticals Corp. - Insight to Impact™

Historical Press Releases:

The press releases posted on this Site are current only as of their date. Nventa Biopharmaceuticals does not update its press releases solely due to a change in the facts described in old press releases. Old press releases are provided only to give readers a sense of past developments and should not be taken as implying that the information contained in them remains accurate. Prior to June 1 2006, Nventa Biopharmaceuticals Corporation was named Stressgen Biotechnologies Corporation.

News Releases - 2007

December 6, 2007

NVENTA COMPLETES ENROLLMENT AND INITIAL DOSING OF SECOND COHORT IN PHASE 1 HSPE7 SAFETY TRIALS

December 4, 2007

NVENTA ANNOUNCES CHANGE IN BOARD OF DIRECTORS

November 27, 2007

NVENTA UPDATES PROGRESS WITH NEW HSPE7 IN PHASE 1 TRIAL IN CERVICAL DYSPLASIA

November 7, 2007

NVENTA BIOPHARMACEUTICALS CORPORATION ANNOUNCES THIRD-QUARTER 2007 FINANCIAL RESULTS

November 5, 2007

NVENTA PRESENTS HSPE7 DATA AT INTERNATIONAL HPV CONFERENCE
-- Preclinical Data Indicate New HspE7 Promotes More Potent Immune Responses --

October 30 , 2007

NVENTA'S CEO TO PRESENT AT THE BIOCOM INVESTOR CONFERENCE 2007
Nventa will also webcast its presentation on Thursday, November 1st.

October 29 , 2007

NEW U.S. PATENT GRANTED FOR NVENTA’S COVALTM HPV FUSIONS TO TREAT PATIENTS WITH HPV-RELATED DISEASES

October 18 , 2007

NVENTA UPDATES PROGRESS OF CERVICAL DYSPLASIA TRIAL WITH NEW HSPE7

October 4 , 2007

NVENTA EXPANDS CLINICAL AND SCIENTIFIC ADVISORY BOARD

October 2 , 2007

NVENTA’S CEO TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES
Webcast:
Nventa will also webcast its presentation on Wednesday, October 10th. The webcast will be available for replay through January 10, 2008 at this link.

September 24 , 2007

NVENTA ANNOUNCES PUBLICATION OF HspE7 DATA
-- HspE7 Demonstrates Ability to Elicit Long-Lasting Tumor Protection In Vivo;
Lead Candidate May Have Utility in HPV-infected Patients With Invasive Cancer and/or HIV --

September 13 , 2007

CONFERENCE CALL:

Nventa will hold a conference call on Thursday, September, 13, 2007, at 9:00 am Eastern Time (6:00 am Pacific Time) to allow securities analysts and shareholders the opportunity to hear Management discuss an update on the progress with HspE7 and other important milestones.

Webcast:
Nventa will also webcast its investor call on Thursday, September 13, 2007, at 9:00 am Eastern Time (6:00 am Pacific Time). The call is being webcast by Vcall and can be accessed starting Sept. 13 through this link. The webcast will be available for replay through October 13, 2007.

September 12 , 2007

NVENTA STRENGTHENS MANAGEMENT TEAM WITH VICE PRESIDENT OF FINANCE
-- David Duncan, Jr. Has Significant Financial Experience in Biotechnology --

September 10 , 2007

NVENTA INITIATES HspE7 PHASE 1 CERVICAL DYSPLASIA TRIAL
-- Conference Call on September 13 to Discuss Phase 1 Trial and Other Major Milestones --

August 22 , 2007

NVENTA ANNOUNCES $8.6 MILLION CLOSING OF SHORT FORM PROSPECTUS OFFERING

August 9 , 2007

NVENTA BIOPHARMACEUTICALS CORPORATION ANNOUNCES SECOND QUARTER 2007 FINANCIAL RESULTS

July 30, 2007

NVENTA ASSEMBLES DISTINQUISHED GROUP OF INTERNATIONAL EXPERTS FOR ITS CLINICAL AND SCIENTIFIC ADVISORY BOARD

July 23, 2007

NVENTA ANNOUNCES PUBLICATION OF FINAL RESULTS OF A PHASE 2 STUDY OF HspE7 IN CERVICAL DYSPLASIA
-- 95% of Patients Had Regression or Stable Disease --

June 15 , 2007

NVENTA ANNOUNCES EXTENSION OF EXPIRY DATE OF WARRANTS ISSUED IN 2005 FINANCING

June 14 , 2007

NVENTA ANNOUNCES ADDITIONAL AMENDMENTS TO EQUITY INCENTIVE PLAN FOR APPROVAL AT SHAREHOLDER MEETING

June 12 , 2007

NVENTA APPOINTS SANDFORD D. SMITH TO BOARD OF DIRECTORS
-- New Member Brings Significant Global Experience in Bio/Pharmaceutical Development and Commercialization -

June 5 , 2007

NVENTA HIRES VICE PRESIDENT OF CORPORATE DEVELOPMENT
-- New Vice President Adds Significant Corporate and Business Development Experience --

May 31, 2007

NVENTA CONSOLIDATES OFFICES INTO SAN DIEGO
-- Company Focusing Resources on Clinical Development of HspE7; Poised to Re-enter Phase 1 Trial --

May 11 , 2007

NVENTA BIOPHARMACEUTICALS CORPORATION ANNOUNCES FIRST QUARTER 2007 FINANCIAL RESULTS

[Read more]

Download a PDF file of this release

May 03 , 2007

NVENTA GRANTED U.S. PATENT COVERING HEAT SHOCK PROTEIN FUSION TO TREAT ANOGENITAL WARTS

[Read more]

Download a PDF file of this release

March 29 , 2007

NVENTA WINS CHALLENGE TO U.S. PATENTS FOR CORE FUSION TECHNOLOGY
-- U.S. Patent and Trademark Office Reissues Composition of Matter and Methods of Use Patents for Company’s Core CoVal™ Fusions --

[Read more]

Download a PDF file of this release

March 14 , 2007

NVENTA BIOPHARMACEUTICALS CORPORATION ANNOUNCES 2006 FINANCIAL RESULTS
-- Company Poised to Re-enter Clinic with Lead Candidate HspE7 plus Adjuvant --

[Read more]

Download a PDF file of this release

March 5 , 2007

NVENTA ANNOUNCES PRESENTATION OF POSITIVE HSPE7 DATA FROM NCI-SPONSORED CLINICAL TRIAL IN CERVICAL DYSPLASIA

-- 78 Percent of Patients Showed Complete Response or Reduction of Lesion Size by More than Fifty Percent --

Download PDF files of the presentation posters

[Read more]

Download a PDF file of this release

January 30 , 2007

NVENTA GRANTED U.S. PATENT COVERING HEAT SHOCK PROTEIN FUSION TO TREAT INFLUENZA

[Read more]

Download a PDF file of this release

January 24 , 2007

NVENTA FINANCING YIELDS TOTAL $16.19 MILLION
-- An Additional $8.23 Million Received From Final Closing of Short-Form Prospectus Offering

sitemap

contact